Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AVPR2 | P30518 | 2/20 | 0.57 |
| ▸ | OXTR | P30559 | 2/20 | 0.57 |
| ▸ | AVPR1A | P37288 | 2/20 | 0.57 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.46 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.46 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.46 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7337847 | 0.87 | AVPR2 (0.52) | AVPR2OXTRAVPR1ACHRNB2CHRNB4 | |
| SCHEMBL7337085 | 0.87 | AVPR2 (0.63) | AVPR2OXTRAVPR1A | |
| SCHEMBL7342147 | 0.83 | SMN1; SMN2 (0.46) | AVPR2OXTRAVPR1ARAB9ASMN1; SMN2 | |
| SCHEMBL7335695 | 0.82 | AVPR2 (0.58) | AVPR2OXTRAVPR1A | |
| SCHEMBL7338077 | 0.82 | AVPR2 (0.77) | AVPR2OXTRAVPR1A | |
| SCHEMBL7338219 | 0.82 | AVPR2 (0.62) | AVPR2OXTRAVPR1A | |
| SCHEMBL7371679 | 0.82 | AVPR1A (0.53) | AVPR2OXTRAVPR1A | |
| SCHEMBL7335534 | 0.81 | AVPR2 (0.57) | AVPR2OXTRAVPR1A | |
| SCHEMBL5739983 | 0.81 | AVPR2 (0.63) | AVPR2AVPR1A | |
| SCHEMBL7334184 | 0.81 | TP53 (0.47) | AVPR2OXTRAVPR1ACHRNB2CHRNB4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-1996022282-A1 | TRICYCLIC BENZAZEPINE VASOPRESSIN ANTAGONISTS | AMERICAN CYANAMID COMPANY (US) | 1996-07-25 | — | — | WO | disclosed |